Iovance Biotherapeutics Statistics
Share Statistics
Iovance Biotherapeutics has 304.78M shares outstanding. The number of shares has increased by 9.12% in one year.
| Shares Outstanding | 304.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.42% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 247.04M |
| Failed to Deliver (FTD) Shares | 10.41K |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 59.33M, so 19.47% of the outstanding shares have been sold short.
| Short Interest | 59.33M |
| Short % of Shares Out | 19.47% |
| Short % of Float | 24.01% |
| Short Ratio (days to cover) | 8.82 |
Valuation Ratios
The PE ratio is -4.31 and the forward PE ratio is -11.82.
| PE Ratio | -4.31 |
| Forward PE | -11.82 |
| PS Ratio | 1607.75 |
| Forward PS | 2.4 |
| PB Ratio | 3.27 |
| P/FCF Ratio | -4.98 |
| PEG Ratio | n/a |
Enterprise Valuation
Iovance Biotherapeutics Inc. has an Enterprise Value (EV) of 1.87B.
| EV / Earnings | -4.22 |
| EV / Sales | 1574.93 |
| EV / EBITDA | -4.38 |
| EV / EBIT | -4.07 |
| EV / FCF | -4.88 |
Financial Position
The company has a current ratio of 2.79, with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.79 |
| Quick Ratio | 2.7 |
| Debt / Equity | 0.13 |
| Total Debt / Capitalization | 11.49 |
| Cash Flow / Debt | -4.77 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.76% and return on capital (ROIC) is -69.19%.
| Return on Equity (ROE) | -0.76% |
| Return on Assets (ROA) | -0.57% |
| Return on Capital (ROIC) | -69.19% |
| Revenue Per Employee | 2.13K |
| Profits Per Employee | -797.19K |
| Employee Count | 557 |
| Asset Turnover | 0 |
| Inventory Turnover | 1.04 |
Taxes
| Income Tax | -3.48M |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -29.63% in the last 52 weeks. The beta is 0.59, so Iovance Biotherapeutics 's price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | -29.63% |
| 50-Day Moving Average | 8.56 |
| 200-Day Moving Average | 9.73 |
| Relative Strength Index (RSI) | 26.25 |
| Average Volume (20 Days) | 7.32M |
Income Statement
In the last 12 months, Iovance Biotherapeutics had revenue of 1.19M and earned -444.04M in profits. Earnings per share was -1.89.
| Revenue | 1.19M |
| Gross Profit | -9.57M |
| Operating Income | -460.56M |
| Net Income | -444.04M |
| EBITDA | -427.43M |
| EBIT | -460.56M |
| Earnings Per Share (EPS) | -1.89 |
Balance Sheet
The company has 114.89M in cash and 75.86M in debt, giving a net cash position of 39.03M.
| Cash & Cash Equivalents | 114.89M |
| Total Debt | 75.86M |
| Net Cash | 39.03M |
| Retained Earnings | -2.01B |
| Total Assets | 991.12M |
| Working Capital | 380.52M |
Cash Flow
In the last 12 months, operating cash flow was -361.82M and capital expenditures -22.29M, giving a free cash flow of -384.11M.
| Operating Cash Flow | -361.82M |
| Capital Expenditures | -22.29M |
| Free Cash Flow | -384.11M |
| FCF Per Share | -1.63 |
Margins
Gross margin is -804.54%, with operating and profit margins of -38.73K% and -37.35K%.
| Gross Margin | -804.54% |
| Operating Margin | -38.73K% |
| Pretax Margin | -37.64K% |
| Profit Margin | -37.35K% |
| EBITDA Margin | -35.95K% |
| EBIT Margin | -38.73K% |
| FCF Margin | -32.31K% |
Dividends & Yields
IOVA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -32.09% |
| FCF Yield | -21.4% |
Analyst Forecast
The average price target for IOVA is $23, which is 290.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 290.5% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on Sep 26, 2013. It was a backward split with a ratio of 1:100.
| Last Split Date | Sep 26, 2013 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | 2.3 |
| Piotroski F-Score | 4 |